Document Detail


Pregabalin for the treatment of fibromyalgia.
MedLine Citation:
PMID:  22725707     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Fibromyalgia (FM) is the most common cause of chronic widespread body pain in humans. Co-morbidities include sleep disturbance, fatigue, impaired physical functioning, altered mood and negative effects on health-related quality of life. Pregabalin inhibits presynaptic release of pronociceptive neurotransmitters in the CNS; this likely underpins its therapeutic benefit in patients with FM.
AREAS COVERED: This review addresses pregabalin pharmacokinetics, efficacy and adverse event (AE) profiles from randomized controlled trials and open-label extension studies in patients with FM. These effects are compared with those of the serotonin norepinephrine reuptake inhibitors, duloxetine and milnacipran that also have FDA approval for the treatment of fibromyalgia.
EXPERT OPINION: At the approved dosages, oral pregabalin has at most a moderate therapeutic benefit above placebo with tolerable side-effects, in no more than 50% of patients with FM. Durability of clinically meaningful (≥ 30%) pain relief in pregabalin-responders has been demonstrated for at least 6-months, but longer-term studies are required as most patients have symptoms for decades. Exclusion of patients with common co-morbidities from the pregabalin RCTs in FM raises questions on the generalizability of the RCT findings to the typical patient seen in clinical practice and so additional investigation is required.
Authors:
Maree T Smith; Brendan J Moore
Related Documents :
22546697 - The complex interplay of depression and falls in older adults: a clinical review.
22521757 - Symptomatic and chondroprotective treatment with collagen derivatives in osteoarthritis...
22607217 - Enhancing attributional style as a resiliency factor in depressogenic stress generation.
22627357 - Seized.
10796487 - Garlic for peripheral arterial occlusive disease.
2211567 - A double-blind, controlled trial in primary care patients with generalized anxiety: a c...
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  13     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-06-25     Completed Date:  2012-11-20     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  1527-33     Citation Subset:  IM    
Affiliation:
Centre for Integrated Preclinical Drug Development & Professor of Pharmacy, The University of Queensland, Steele Building, St Lucia Campus, Brisbane, Queensland, 4072, Australia. maree.smith@uq.edu.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Analgesics / pharmacology,  therapeutic use*
Fibromyalgia / drug therapy*
Humans
Serotonin Uptake Inhibitors / therapeutic use
gamma-Aminobutyric Acid / analogs & derivatives*,  pharmacology,  therapeutic use
Chemical
Reg. No./Substance:
0/Analgesics; 0/Serotonin Uptake Inhibitors; 55JG375S6M/pregabalin; 56-12-2/gamma-Aminobutyric Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy.
Next Document:  Promiscuous mating in the harem-roosting fruit bat, Cynopterus sphinx.